Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Post-transplantation Cyclophosphamide (PTCy)
58%
Acute Myeloid Leukemia
52%
Hematological Malignancies
35%
CD8+ T Cells
31%
Allogeneic Transplant
29%
Clofarabine
29%
Multiple Myeloma
29%
Donor Lymphocyte Infusion
29%
Graft-versus-host Disease (GvHD)
29%
Overall Survival
26%
Cancer Diagnosis
21%
Remission
21%
Multiple Myeloma Patients
21%
Lymphoma
20%
Relapsed or Refractory Acute Myeloid Leukemia
19%
T-cell chimerism
17%
Splenomegaly
17%
Single Center
16%
Retrospective Cohort Study
16%
Patients with Hematological Malignancies
16%
T Cells
15%
High-dose Chemotherapy
14%
Adult Hematopoietic Stem Cells
14%
Multilineage
14%
Intensive Care
14%
Brentuximab Vedotin
14%
Extent of Resection
14%
Leukemia Progression
14%
Hodgkin Lymphoma
14%
Relapsed or Refractory
14%
Occupational Aspirations
14%
Doxycycline
14%
Primary Graft Dysfunction
14%
T Cell Reconstitution
14%
Common Variable Immune Deficiency
14%
Treatment Complications
14%
Chimeric Antigen Receptor T-cell Therapy
14%
Confidence Interval
14%
Diffuse Large B-cell Lymphoma (DLBCL)
14%
Functional Impairment
14%
Complication Prevention
14%
Pilot Randomized Controlled Trial
14%
Relative Risk
14%
Marrow Transplantation
14%
Total Body Irradiation
14%
Systematic Meta-analysis
14%
Time Effect
14%
Haploidentical Transplantation
14%
Hematopoietic Stem Cell Transplantation
14%
Medicine and Dentistry
Transplantation
61%
Acute Myeloid Leukemia
48%
Hematologic Malignancy
47%
Cyclophosphamide
43%
Stem Cell Transplant
33%
Hematopoietic Cell
29%
Cell Transplantation
29%
Clofarabine
29%
Leukemia Relapse
29%
Donor Lymphocyte Infusion
29%
Overall Survival
24%
Hematopoietic Stem Cell Transplantation
23%
Graft Versus Host Reaction
23%
Diseases
22%
Leukemia
18%
Cytopenia
17%
End of Life Care
14%
Cytotoxic T-Cell
14%
Graft Failure
14%
B Cell
14%
Prevalence
14%
Busulfan
14%
Classical Hodgkin Lymphoma
14%
Splenomegaly
14%
Duodenum
14%
Randomized Controlled Trial
14%
Common Variable Immunodeficiency
14%
Whole Body Radiation
14%
Retrospective Cohort Study
14%
Anaplastic Large Cell Lymphoma
14%
Pancreaticoduodenectomy
14%
Liver Dysfunction
14%
Chimeric Antigen Receptor T-Cell Immunotherapy
14%
Breast Implant
14%
Fludarabine
14%
Intensive Care
14%
T-Cell Lymphoma
14%
Rituximab
14%
Cohort Study
14%
Systematic Review
14%
Superior Mesenteric Artery Syndrome
14%
Brentuximab Vedotin
14%
Sensitivity and Specificity
14%
Chimera
14%
Allogeneic Stem Cell Transplantation
14%
Hodgkin's Lymphoma
12%
Diffuse Large B-Cell Lymphoma
10%
Immunity
9%
Symptomatic Treatment
9%
Positron Emission Tomography
9%